Arrowhead Pharmaceuticals, Inc. Forecast, price target & analysts
Arrowhead Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Arrowhead Pharmaceuticals, Inc. Classifications & Recommendation:
Arrowhead Pharmaceuticals, Inc. Price Target
| Target Price | $62.22 |
| Price | $67.79 |
| Deviation |
8.22%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Arrowhead Pharmaceuticals, Inc. 2027 .
The average Arrowhead Pharmaceuticals, Inc. target price is $62.22.
This is
8.22%
register free of charge
$105.00
54.89%
register free of charge
$17.17
74.67%
register free of charge
|
|
| A rating was issued by 20 analysts: 15 Analysts recommend Arrowhead Pharmaceuticals, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arrowhead Pharmaceuticals, Inc. stock has an average upside potential 2027 of
8.22%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 829.45 | 424.89 |
| 23,264.79% | 48.77% | |
| EBITDA Margin | 14.74% | -61.96% |
| 100.09% | 520.32% | |
| Net Margin | -0.20% | -105.22% |
| 100.00% | 53,442.78% |
16 Analysts have issued a sales forecast Arrowhead Pharmaceuticals, Inc. 2026 . The average Arrowhead Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Arrowhead Pharmaceuticals, Inc. EBITDA forecast 2026. The average Arrowhead Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Arrowhead Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Arrowhead Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.01 | -3.29 |
| 99.80% | 32,800.00% | |
| P/E | negative | |
| EV/Sales | 20.97 |
16 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast for earnings per share. The average Arrowhead Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Arrowhead Pharmaceuticals, Inc....
Current Arrowhead Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 11 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Dec 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 02 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Dec 01 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Dec 01 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Nov 26 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 11 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Dec 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 02 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Dec 01 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Dec 01 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Nov 26 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
